Johnson & Johnson (JNJ) Capital Expenditures (2009 - 2026)
Johnson & Johnson (JNJ) posted Capital Expenditures of $1.3 billion for Q2 2026, up 25.93% sequentially from $1.0 billion in Q1 2026, and up 26.65% YoY from $1.0 billion in Q2 2025.
Johnson & Johnson (JNJ) Capital Expenditures (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Capital Expenditures for 18 years, with the latest figure at $1.3 billion in Q2 2026.
- Quarterly Capital Expenditures rose 26.65% year-over-year to $1.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.4 billion (up 19.76% YoY) and the FY2025 annual result came in at $4.8 billion, up 9.22% from the prior year.
- Capital Expenditures grew to $1.3 billion in Q2 2026 per JNJ's latest filing, from $1.0 billion in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.8 billion in Q4 2025 and troughed at $607.0 million in Q2 2022.
- A 5-year average of $1.2 billion and a median of $1.0 billion in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures soared 42.17% in 2023, then decreased 13.17% in 2024.
- Over 5 years, Capital Expenditures stood at $607.0 million in 2022, then soared by 161.78% to $1.6 billion in 2023, then advanced by 1.45% to $1.6 billion in 2024, then advanced by 13.96% to $1.8 billion in 2025, then fell by 28.09% to $1.3 billion in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $1.3 billion, $1.0 billion, and $1.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 1.32 Bn |
| Jun 28, 2026 | 1.32 Bn |
| Mar 29, 2026 | 1.05 Bn |
| Mar 29, 2026 | 1.05 Bn |
| Dec 28, 2025 | 1.84 Bn |
| Dec 28, 2025 | 1.84 Bn |
| Sep 28, 2025 | 1.16 Bn |
| Sep 28, 2025 | 1.16 Bn |
| Jun 29, 2025 | 1.04 Bn |
| Jun 29, 2025 | 1.04 Bn |
| Mar 30, 2025 | 795.00 Mn |
| Mar 30, 2025 | 795.00 Mn |
| Dec 29, 2024 | 1.61 Bn |
| Dec 29, 2024 | 1.61 Bn |
| Sep 29, 2024 | 1.03 Bn |
| Sep 29, 2024 | 1.03 Bn |
| Jun 30, 2024 | 976.00 Mn |
| Jun 30, 2024 | 976.00 Mn |
| Mar 31, 2024 | 807.00 Mn |
| Mar 31, 2024 | 807.00 Mn |